Analyst Price Target is $8.83
▲ +244.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $8.83, with a high forecast of $14.00 and a low forecast of $5.00. The average price target represents a 244.73% upside from the last price of $2.56.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.